Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study

The American Journal of Medicine
J Hoffmann, M Spengler

Abstract

To compare the therapeutic potential of acarbose, metformin, or placebo as first line treatment in patients with non-insulin-dependent diabetes mellitus (NIDDM). Ninety-six patients with NIDDM (35-70 years of age, body mass index (BMI) < or = 35 kg/m2, insufficiently treated with diet alone, glycated hemoglobin (HbA1c; 7% to 11%) were randomized into 3 groups and treated for 24 weeks with acarbose, 3 x 100 mg/day, or metformin, 2 x 850 mg/day, or placebo. Efficacy, based on HbA1c (primary efficacy criterion), fasting blood glucose (BG) and insulin, 1 hour postprandial BG and insulin (after standard meal test), postprandial insulin increase, plasma lipid profile, and tolerability, based on subjective symptoms and laboratory values were determined every 6 weeks. Analysis of covariance was performed for endvalues with adjustment on baseline values. Ninety-four patients were valid for efficacy evaluation. Both active drugs showed the same improvement of efficacy criteria compared with placebo. Baseline adjusted means at endpoint were as follows: BG, fasting and 1 hour postprandial, 9.2 mM and 10.9 mM with placebo, 7.6 mM and 8.7 mM with acarbose, and 7.8 mM and 9.0 mM with metformin; HbA1c was 9.8% with placebo, 8.5% with acarbose,...Continue Reading

References

Jun 1, 1991·Diabetes Care·A M Fontbonne, E M Eschwège
Jul 1, 1990·Diabetic Medicine : a Journal of the British Diabetic Association·S Josephkutty, J M Potter
Aug 31, 1995·The New England Journal of Medicine·M StumvollJ E Gerich
Jun 1, 1993·British Heart Journal·P J Savage, M F Saad
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Aug 1, 1995·Drugs·B H Wolffenbuttel, T W van Haeften
Sep 1, 1995·Diabetes Care·D L WingardA Ferrara

❮ Previous
Next ❯

Citations

May 15, 2013·Future Cardiology·Timothy RaymondA Michael Lincoff
Jan 19, 2005·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Alice Y Y Cheng, I George Fantus
Jan 6, 2012·Wiener klinische Wochenschrift·Bernhard Ludvik, Guntram Schernthaner
Sep 3, 2013·Diabetes Research and Clinical Practice·Jun-Sing WangUNKNOWN acarbose/metformin fixed-dose combination study investigators
Nov 17, 2015·Postgraduate Medicine·Tamer Yacoub
Dec 26, 2007·Current Medical Research and Opinion·S M BeardR A Malik
Sep 24, 2004·Current Medical Research and Opinion·T P DidangelosD T Karamitsos
Dec 25, 2007·Current Medical Research and Opinion·Andrew J Krentz
Jun 26, 2014·Expert Opinion on Pharmacotherapy·Shashank R JoshiSanjay Kalra
Dec 18, 2012·Expert Opinion on Drug Safety·Stephanie Aleskow SteinStephen N Davis
Jun 3, 2015·Current Cardiology Reports·Barbara E StähliJean-Claude Tardif
Jun 23, 2009·Expert Opinion on Drug Safety·Joanna Mitri, Osama Hamdy
Sep 9, 2008·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·John H B Scarpello, Harry C S Howlett
Mar 21, 2002·Diabetes, Obesity & Metabolism·H HaunerH Toplak
Jul 27, 2007·International Journal of Obesity : Journal of the International Association for the Study of Obesity·A Golay
Jun 20, 2002·Pharmazie in unserer Zeit·Holger Neye
Sep 1, 2005·Obesity Research·Warren G ThompsonMichael B Zemel
Aug 23, 2006·Cardiology in Review·Kerri L PalamaraWilliam H Frishman
Jan 31, 2008·Diabetes/metabolism Research and Reviews·Patrick J Boyle, John Zrebiec
Apr 23, 2005·The Cochrane Database of Systematic Reviews·F A Van de LaarC Van Weel
Oct 21, 2010·The Mount Sinai Journal of Medicine, New York·Amulya T SiramMaria Skamagas
May 20, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Mark C Granberry, Vivian A Fonseca
May 17, 2011·Diabetes, Obesity & Metabolism·A Chaudhuri, P Dandona
Oct 9, 2019·Expert Opinion on Pharmacotherapy·Maka S Hedrington, Stephen N Davis
Sep 30, 2016·Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis·Abdullah K Al-HwieshNehad Al-Audah
Oct 3, 2006·Current Opinion in Anaesthesiology·G M Hall, R Ruggier
Jan 2, 2001·Endocrine Reviews·S MatthaeiH U Häring
Jul 30, 2015·The Cochrane Database of Systematic Reviews·Bianca HemmingsenThomas P Almdal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.